Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell (Q53223555)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2006

Language	Label	Description	Also known as
English	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell	scientific article published in November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

phase II clinical trial

0 references

quality of life

1 reference

based on heuristic

inferred from title

Christopher Logothetis

10

object named as

Christopher Logothetis

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

author name string

Nizar M Tannir

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Lorenzo Cohen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Xuemei Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Peter Thall

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Paul F Mathew

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Eric Jonasch

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Arlene Siefker-Radtke

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Lance C Pagliaro

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Chaan S Ng

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

107

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

2254-2261

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal chemotherapy in ovarian cancer remains experimental

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Modern Applied Statistics with S

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22253

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22253

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17029276

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53223555&oldid=2282500664"